EDTA chelation therapy for cardiovascular disease: a systematic review

التفاصيل البيبلوغرافية
العنوان: EDTA chelation therapy for cardiovascular disease: a systematic review
المؤلفون: Ping Wu, Dugald Seely, Edward J Mills
المصدر: BMC Cardiovascular Disorders, Vol 5, Iss 1, p 32 (2005)
BMC Cardiovascular Disorders
بيانات النشر: Springer Nature
مصطلحات موضوعية: medicine.medical_specialty, lcsh:Diseases of the circulatory (Cardiovascular) system, business.industry, Alternative medicine, Disease, Chelation Therapy, law.invention, Randomized controlled trial, Cardiovascular Diseases, law, lcsh:RC666-701, medicine, Physical therapy, Humans, Chelation therapy, Intensive care medicine, business, Cardiology and Cardiovascular Medicine, Edetic Acid, Chelating Agents, Randomized Controlled Trials as Topic, Research Article
الوصف: Background Numerous practitioners of both conventional and complementary and alternative medicine throughout North America and Europe claim that chelation therapy with EDTA is an effective means to both control and treat cardiovascular disease. These claims are controversial, and several randomized controlled trials have been completed dealing with this topic. To address this issue we conducted a systematic review to evaluate the best available evidence for the use of EDTA chelation therapy in the treatment of cardiovascular disease. Methods We conducted a systematic review of 7 databases from inception to May 2005. Hand searches were conducted in review articles and in any of the trials found. Experts in the field were contacted and registries of clinical trials were searched for unpublished data. To be included in the final systematic review, the studies had to be randomized controlled clinical trials. Results A total of seven articles were found assessing EDTA chelation for the treatment of cardiovascular disease. Two of these articles were subgroup analyses of one RCT that looked at different clinical outcomes. Of the remaining five studies, two smaller studies found a beneficial effect whereas the other three exhibited no benefit for cardiovascular disease from the use of EDTA chelation therapy. Adverse effects were rare but those of note included a few cases of hypocalcemia and a single case of increased creatinine in a patient on the EDTA intervention. Conclusion The best available evidence does not support the therapeutic use of EDTA chelation therapy in the treatment of cardiovascular disease. Although not considered to be a highly invasive or harmful therapy, it is possible that the use of EDTA chelation therapy in lieu of proven therapy may result in causing indirect harm to the patient.
اللغة: English
تدمد: 1471-2261
DOI: 10.1186/1471-2261-5-32
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47f184f7933f89ba5a8259dfcdb2020aTest
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....47f184f7933f89ba5a8259dfcdb2020a
قاعدة البيانات: OpenAIRE
الوصف
تدمد:14712261
DOI:10.1186/1471-2261-5-32